Is there still a role for systematic biopsy after targeted biopsy for the detection of clini-cally significant prostate cancer in MRI suspicious lesions?

In conclusion, SB adds limited diagnostic value, with TB alone being sufficient for detecting csPCa cases in patients with MRI-visible lesions. The results suggest that SB may be safely omitted in selected patients to reduce biopsy burden and lead to better clinical outcomes.